CRMD

CorMedix Inc.

7.74 USD

Last updated Sep 16, 03:15 UTC

Yesterday HIGH

$7.94

Yesterday LOW

$7.75

52w HIGH

$13.02

52w LOW

$6.12

EPS

0.29

PE

26.69

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

CorMedix Inc. stock is up 0.91% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.29% of the previous 16 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 10 PUTs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

12 Aug 19:37	19 Mar, 2027	8.00	PUT	784	1766
14 Aug 17:09	19 Mar, 2027	8.00	PUT	172	3046
14 Aug 17:09	19 Mar, 2027	8.00	PUT	748	3046
14 Aug 17:20	19 Mar, 2027	8.00	PUT	919	3046
17 Aug 16:42	19 Mar, 2027	14.00	PUT	124	15
17 Aug 17:19	19 Mar, 2027	14.00	PUT	224	15
17 Aug 17:41	19 Mar, 2027	14.00	PUT	142	15
17 Aug 18:18	19 Mar, 2027	14.00	PUT	158	15
17 Aug 19:29	19 Mar, 2027	14.00	PUT	190	15
02 Sep 19:37	21 Jan, 2028	10.00	PUT	100	18

Advanced Data Unlock

Benzinga Insights

Thu May 14, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Newsdesk

Thu May 14, 2026

CorMedix shares are trading higher after the company reported better-than-expected Q1 financial results.
Benzinga Newsdesk

Thu May 14, 2026

Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 16.22 percent. This is a 43.33 percent increase over earnings of $0.30 per share from the same
Benzinga Insights

Thu May 14, 2026

Earnings Scheduled For May 14, 2026
Benzinga Newsdesk

Tue Apr 28, 2026

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
Benzinga Newsdesk

Tue Apr 28, 2026

Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

Citizens analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $19 price target.
Benzinga Newsdesk

Tue Apr 28, 2026

Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

Leerink Partners analyst Roanna Ruiz maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
Vandana Singh

Mon Apr 27, 2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix says Phase 3 ReSPECT data show rezafungin is non-inferior in fungal prevention, supporting FDA filing plans and a $2 billion market outlook.
Benzinga Newsdesk

Mon Apr 27, 2026

Needham Maintains Buy on Cormedix, Raises Price Target to $15

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $14 to $15.
Benzinga Newsdesk

Mon Apr 27, 2026

CorMedix Announces Phase III Topline Results From Global ReSPECT Clinical Trial Evaluating REZZAYO For Prophylaxis Of IFDs In Adult Patients Undergoing Allogeneic HSCT; Study Meets Primary Endpoint

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –– Study showed favorable benefit for toxicity related discontinuations and drug-drug